Salesforce (CRM) Wins AstraZeneca Deal, Becomes the Unified Global Platform
TipRanks (Thu, 4-Dec 5:12 PM ET)
Former FDA commissioners castigate plan to change vaccine approval standards
Seeking Alpha News (Wed, 3-Dec 5:40 PM ET)
Is AstraZeneca’s Stock (AZN) a Good Investment Right Now?
TipRanks (Tue, 2-Dec 2:00 PM ET)
FDA top drugs official Pazdur retiring shortly after starting - report
Seeking Alpha News (Tue, 2-Dec 11:48 AM ET)
Vaccine panel head who opposed COVID restrictions elevated to senior HHS role
Seeking Alpha News (Tue, 2-Dec 10:11 AM ET)
Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now
Globe Newswire (Tue, 2-Dec 8:30 AM ET)
TipRanks (Tue, 2-Dec 7:30 AM ET)
Pfizer’s Balanced Outlook: Strong Performance Amidst Upcoming Challenges and Strategic Opportunities
TipRanks (Tue, 2-Dec 2:55 AM ET)
Moderna, vaccine makers decline following FDA official comments on future approvals
Seeking Alpha News (Mon, 1-Dec 10:54 AM ET)
Best and worst performing assets and sectors since ChatGPT launched
Seeking Alpha News (Mon, 1-Dec 10:06 AM ET)
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
Pfizer trades on the NYSE stock market under the symbol PFE.
As of December 5, 2025, PFE stock price climbed to $26.03 with 43,529,062 million shares trading.
PFE has a beta of 0.59, meaning it tends to be less sensitive to market movements. PFE has a correlation of 0.14 to the broad based SPY ETF.
PFE has a market cap of $147.99 billion. This is considered a Large Cap stock.
Last quarter Pfizer reported $17 billion in Revenue and $.87 earnings per share. This beat revenue expectation by $102 million and exceeded earnings estimates by $.22.
In the last 3 years, PFE traded as high as $54.93 and as low as $20.92.
The top ETF exchange traded funds that PFE belongs to (by Net Assets): VTI, VOO, IVV, SPY, VTV.
PFE has underperformed the market in the last year with a return of +10.0%, while SPY returned +14.0%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in PFE shares. However, PFE has outperformed the market in the last 3 month and 2 week periods, returning +7.8% and +6.7%, while SPY returned +5.9% and +5.1%, respectively. This indicates PFE has been having a stronger performance recently.
PFE support price is $25.23 and resistance is $26.17 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PFE shares will trade within this expected range on the day.